Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
Condition: HIV Infections
Intervention: Biological: MVA-mBN32
3 Completed Phase 1 Safety Study of Two Experimental HIV Vaccines
Conditions: AIDS Vaccines;   HIV Infections;   HIV-1
Interventions: Drug: VRC-HIVADV027-00-VP;   Drug: VRC-HIVADV038-00-VP
4 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
5 Completed A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN
6 Completed A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
7 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
8 Completed Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
9 Completed A Study to Test the Safety of Three Experimental HIV Vaccines
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: HIV p24/MF59 Vaccine;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
10 Completed Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: Placebo;   Biological: rMVA vaccine
11 Withdrawn Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
12 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: Env 2-3;   Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
13 Completed A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
Condition: HIV Infections
Interventions: Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent;   Biological: HIV-1 Peptide Immunogen, Multivalent
14 Completed Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP
15 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
16 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
17 Completed A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
18 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1MN
19 Completed A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Condition: HIV Infections
Interventions: Biological: HIV p17/p24:Ty-VLP;   Biological: Aluminum hydroxide
20 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years